| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/06/2009 | EP1861073B1 Process for the production of calcium compositions in a continuous fluid bed |
| 05/06/2009 | EP1828199B1 Thieno-pyridine derivatives as gaba-b allosteric enhancers |
| 05/06/2009 | EP1828185B1 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors |
| 05/06/2009 | EP1827500B1 Pegylated liposomal doxorubicin in combination with ecteinescidin 743 |
| 05/06/2009 | EP1807065A4 Methods and compositions for treating nephrogenic diabetes insipidus |
| 05/06/2009 | EP1802621B1 Crf receptor antagonists and methods relating thereto |
| 05/06/2009 | EP1783120B1 Method of obtaining 2-amino-6-alkyl-amino-4,5,6,7-tetrahydrobenzothiazoles |
| 05/06/2009 | EP1778655B1 2 - { - 3 2 - (phenyl)-oxazol-4-ylmethoxyl-cyclohexylmethoxy}-propionic acid derivatives used as ppar ligands (peroxisome proliferator-activated receptors) for the treatment of hyperlipidaemie and diabetes |
| 05/06/2009 | EP1755393A4 Methods of diminishing co-abuse potential |
| 05/06/2009 | EP1745069B1 Therapeutic use of growth factor nsg33 |
| 05/06/2009 | EP1729774A4 Pyrrolidine compounds |
| 05/06/2009 | EP1720864B1 Benzimidazol substituted thiophene derivatives with activity on ikk3 |
| 05/06/2009 | EP1699461A4 Treatment of hepatic fibrosis with imatinib mesylate |
| 05/06/2009 | EP1682544A4 Hydroxylamine substituted imidazo ring compounds |
| 05/06/2009 | EP1670757B1 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors |
| 05/06/2009 | EP1670478A4 Heteroaromatic selective inhibitors of neuronal nitric oxide synthase |
| 05/06/2009 | EP1667682A4 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| 05/06/2009 | EP1667678B1 Animal feed composition |
| 05/06/2009 | EP1648878B1 Piperidine compounds and pharmaceutical compositions containing them |
| 05/06/2009 | EP1599453B1 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis |
| 05/06/2009 | EP1581235B1 Use of spongosine (2-methoxyadenosein) for the treatment of pain, in particular hyperalgesia |
| 05/06/2009 | EP1572711B1 Anhydrous crystalline azido cytosine hemisulfate derivative |
| 05/06/2009 | EP1572157B1 Formulation for fast dissolution of lipophilic compounds |
| 05/06/2009 | EP1569902B1 Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 05/06/2009 | EP1563092A4 Assays and methods based on microcompetition with a foreign polynucleotide |
| 05/06/2009 | EP1562603B1 Novel medicaments for the treatment of chronic obstructive pulmonary diseases |
| 05/06/2009 | EP1554240B1 Substituted tetralins and indanes and their use |
| 05/06/2009 | EP1478398B1 New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors |
| 05/06/2009 | EP1474174B1 Composition for oral or rectal administration |
| 05/06/2009 | EP1465861B1 Alpha-(n-sulphonamido)acetamide derivatives as beta-amyloid inhibitors |
| 05/06/2009 | EP1458355B1 Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol |
| 05/06/2009 | EP1436264B9 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain |
| 05/06/2009 | EP1430074B1 Aminoglycoside lipid derivatives for transfection |
| 05/06/2009 | EP1420759B1 Pharmaceutical compositions for the treatment of asthma |
| 05/06/2009 | EP1414525B1 2-(3,5-bis-trifluoromethyl-phenyl)-n-¬6-(1,1-dioxo-1.lambda.6-thiomorpholin-4-yl)-4-(2-methyl or 4-fluoro-2-methyl substituted)phenyl-pyridin-3-yl -n-methyl-isobutyramide |
| 05/06/2009 | EP1385506B1 Acylated piperidine derivates as melanocortin-4 receptor agonists |
| 05/06/2009 | EP1373265B1 Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use as adenosine receptor-selective ligands |
| 05/06/2009 | EP1363933B1 Sterol derivatives, liposomes comprising sterol derivatives and method for loading liposomes with active substances |
| 05/06/2009 | EP1343782B1 Pyrimidineamines as angiogenesis modulators |
| 05/06/2009 | EP1335661B1 Production of microspheres |
| 05/06/2009 | EP1326865B1 Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| 05/06/2009 | EP1313447A4 Palatable oral coenzyme q liquid |
| 05/06/2009 | EP1308440B1 Piperidine derivatives and drugs containing these derivatives as the active ingredient |
| 05/06/2009 | EP1274851B1 A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus orf2, and an antigenic polypeptide |
| 05/06/2009 | EP1272193B1 Synergistic combination therapy for treating cancer |
| 05/06/2009 | EP1268421B1 Phenyl-substituted indoles as histamine h3-receptor antagonists |
| 05/06/2009 | EP1244435B9 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
| 05/06/2009 | EP1242082B1 Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders |
| 05/06/2009 | EP1235562B1 Chronotherapeutic diltiazem formulations and the administration thereof |
| 05/06/2009 | EP1200114B1 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 05/06/2009 | EP1173155A4 Gum pad for delivery of medication to mucosal tissues |
| 05/06/2009 | EP1152750B1 Spontaneously dispersible n-benzoyl staurosporine compositions |
| 05/06/2009 | EP1089724B1 Cyano substituted oleanolic acid derivatives as no production inhibitors |
| 05/06/2009 | EP0935417B1 Enteric formulations of proanthocyanidin polymer antidiarrheal compositions |
| 05/06/2009 | CN201230969Y Coated creatine |
| 05/06/2009 | CN101426913A Compositions and methods of using siRNA to knockdown gene expression and to improve solid organ and cell transplantation |
| 05/06/2009 | CN101426904A Cancerous disease modifying antibodies 141205-05 |
| 05/06/2009 | CN101426806A Oxa-steroids derivatives as selective progesterone receptor modulators |
| 05/06/2009 | CN101426796A Meridamycin analogues for the treatment of neurodegenerativedisorders |
| 05/06/2009 | CN101426793A Methods for the preparation of hcv polymerase inhibitors |
| 05/06/2009 | CN101426792A Pyrazolopyrimidines as therapeutic agents |
| 05/06/2009 | CN101426791A Purine derivatives with activity to the adenosine A2A receptor |
| 05/06/2009 | CN101426790A Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use |
| 05/06/2009 | CN101426785A Adenosine A3 receptor agonists |
| 05/06/2009 | CN101426783A Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 05/06/2009 | CN101426780A Cyclohexylimidazole lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 05/06/2009 | CN101426778A N-substituted-azacyclylamines as histamine-3 antagonists |
| 05/06/2009 | CN101426777A Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists |
| 05/06/2009 | CN101426775A Oxadiazolidinedione compound |
| 05/06/2009 | CN101426774A Azolecarboxamide derivative |
| 05/06/2009 | CN101426773A 5-phenyl-3-benzyl-oxazolidin-2-one derivatives and related compounds as metabotropic glutamate receptor potentiators for the treatment of neurological and psychiatric disorders |
| 05/06/2009 | CN101426772A Benzotriazine inhibitors of kinases |
| 05/06/2009 | CN101426770A Imidazole derivatives for use as EDG-1 antagonists |
| 05/06/2009 | CN101426766A Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors |
| 05/06/2009 | CN101426765A Crystalline forms of a dimethylphenyl compound |
| 05/06/2009 | CN101426764A Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| 05/06/2009 | CN101426763A Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| 05/06/2009 | CN101426753A Hydroxylated long-chain resveratrol derivatives useful as neurotrophic agents |
| 05/06/2009 | CN101426534A Methods and compositions for detecting and treating retinal diseases |
| 05/06/2009 | CN101426524A Compositions and methods for mucosal vaccination |
| 05/06/2009 | CN101426510A Therapy-enhancing glucan |
| 05/06/2009 | CN101426509A Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines |
| 05/06/2009 | CN101426508A Hexose compounds to treat cancer |
| 05/06/2009 | CN101426507A Use of polyamines with antibiotics |
| 05/06/2009 | CN101426506A Novel anthraquinones and process for the preparation and method of use thereof |
| 05/06/2009 | CN101426505A Dihydrothienopyrimidine for treating inflammatory disorders |
| 05/06/2009 | CN101426504A Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom |
| 05/06/2009 | CN101426503A Compositions and treatments for inhibiting kinase and/or HMG-COA reductase |
| 05/06/2009 | CN101426502A Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
| 05/06/2009 | CN101426501A The use of beta-aminoalcohols for the treatment of inflammatory disorders and pain |
| 05/06/2009 | CN101426500A Combination of dipeptidyl peptidase-iv inhibitor and a cannabinoid cb1 receptor antagonist for the treatment of diabetes and obesity |
| 05/06/2009 | CN101426499A Modulators of muscarinic receptors |
| 05/06/2009 | CN101426498A Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof |
| 05/06/2009 | CN101426497A Small molecule apoptosis promoters |
| 05/06/2009 | CN101426496A Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist |
| 05/06/2009 | CN101426495A CB1 antagonists and inverse agonists |
| 05/06/2009 | CN101426494A Use of escitalopram for improving cognition |
| 05/06/2009 | CN101426493A Treatment of peripheral arterial occlusive disease |
| 05/06/2009 | CN101426492A Inhibitor of increase in postprandial blood insulin level |
| 05/06/2009 | CN101426491A GIP secretion inhibitor |